Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

GT Biopharma, Inc. (GTBP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8900-0.1400 (-6.90%)
At close: 04:00PM EDT
1.9800 +0.09 (+4.76%)
After hours: 04:47PM EDT
Advertisement

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • A
    Alex
    Lol joke of a stock
    Bearish
  • N
    NHL
    Wainwright reiterated buy rating and $25 stock price
  • S
    Slippery
    this thing will be 50 cents before it sees $3.00 ... if it ever sees $3.... I'm hoping it makes it - saves lives but they got a long long way and a terrible market.
  • v
    victoria
    Thoughts on this drop today???
  • M
    Melly
    if you don't have a ton of cash to waste, don't bother.
  • J
    Joaquin
    I still don’t see this stock taking off soon. It is stuck in the mud and going nowhere. I’m staying neutral and holding for now.
  • A
    Andrew
    From Roth: Roth cuts GT Biopharma to Neutral after filings for TriKE programs pushed back 15:32 GTBP Roth Capital analyst Tony Butler downgraded GT Biopharma to Neutral from Buy with a price target of $3, down from $9, after the company provided a Q2 business update and said an IND filing from the first of the second-generation tri-specific NK cell engagers, or TriKEs, is being pushed back almost one year until 2023. While he is "enthusiastic about the program," the delay leads him to lower his rating and price target until clarity on the IND filing becomes evident, Butler tells investors.
  • A
    Aaron
    For the longs out there, here is my take on things:

    - In the long-run, Tony leaving will be a good thing. I think his replacement will be very strong on the medical side and they will find someone who conducts interviews in a professional manner which Tony often lacked.

    -Remember - Tony still owns $3M shares and is still on the Board, as of now. Does he want to see GT succeed? Yes!!! If you look at the history of Iovance, you will see a similar progression. He built up the framework and then left before the stock made a significant move. He left June 1, 2013. The stock was at $6! Now, it’s quadruple that amount and was a lot higher.

    -Lastly, I think the additions of Stacy Herb and Leslie Bransfield are strong ones.

    Stay the course. In my opinion - in 3-5 years, you will be well rewarded. If you want to make a quick buck, you’re not in the right place.
    Bullish
  • m
    miUSAxl
    Umm, did anyone notice what Fidelity did? They went from 1 fund w/ 6k shares to 3 funds w/ over 120k shares. Additionally, there were 10 institutions holding shares to 15. This is within the last two weeks. Just an FYI
    Bullish
  • Q
    Qwerty McMullen
    Small Bio stocks like this sink gradually over time when there are no NRs. One hopes that the spike they get on bits of news counters that somewhat. Trike sounds like a strong addition to a growing arsenal of cancer drugs. Could be a strong candidate for a buy out.
  • J
    James
    Some very nice moves by Tony over the last couple of weeks- bringing in new board members, advisory board appointments, and a new CFO. All positive additions. Hopefully, good news will follow in the near term.
Advertisement
Advertisement